​

Immuneering (IMRX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

IMRX Stock Forecast

Immuneering (IMRX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $30.00, with a high of $30.00 and a low of $30.00. This represents a 376.19% increase from the last price of $6.30.

- $6 $12 $18 $24 $30 High: $30 Avg: $30 Low: $30 Last Closed Price: $6.3

IMRX Stock Rating

Immuneering stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (63.64%), 4 Hold (36.36%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 4 7 Strong Sell Sell Hold Buy Strong Buy

IMRX Price Target Upside V Benchmarks

TypeNameUpside
StockImmuneering376.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$30.00$30.00
Last Closing Price$6.30$6.30$6.30
Upside/Downside-376.19%376.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2523---5
Sep, 2523---5
Aug, 25231--6
Jul, 25231--6
Jun, 25231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 25, 2025Jay OlsonOppenheimer$30.00$9.23225.03%376.19%
Apr 02, 2024Graig SuvannavejhMizuho Securities$8.00$2.75190.91%26.98%
Mar 15, 2024Michael YeeJefferies$3.00$1.9157.07%-52.38%
Sep 30, 2022Swapnil MalekarPiper Sandler$41.00$15.50164.52%550.79%
Jul 09, 2022Geulah LivshitsLoop Capital Markets$18.00$7.28147.25%185.71%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 25, 2025OppenheimerOutperformOutperformhold
May 07, 2025OppenheimerOutperformOutperformhold
Dec 13, 2024Morgan StanleyUnderweightdowngrade
Apr 19, 2023Mizuho SecuritiesBuyupgrade
Jul 25, 2022Piper SandlerOverweightOverweighthold
Jul 09, 2022Chardan CapitalBuyinitialise

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-500 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.27$-1.87$-1.88$-2.04K----
Avg Forecast$-3.30$-1.93$-1.82$-1.82$-1.57$-1.74$-1.50$-0.86
High Forecast$-3.30$-1.93$-1.72$-1.62$-0.95$-0.83$-0.74$-0.86
Low Forecast$-3.30$-1.93$-1.87$-2.04$-2.33$-2.49$-2.54$-0.86
Surprise %-61.52%-3.11%3.30%111757.14%----

Revenue Forecast

$0 $15M $30M $45M $60M $75M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.08M$316.95K------
Avg Forecast$2.44M$447.43K$455.00-$1.09M$21.27M$33.40M$70.43M
High Forecast$2.44M$447.43K$455.00-$1.09M$21.27M$33.40M$70.43M
Low Forecast$2.44M$447.43K$455.00-$1.09M$21.27M$33.40M$70.43M
Surprise %-14.91%-29.16%------

Net Income Forecast

$-65B $-52B $-39B $-26B $-13B $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-33.54M$-49.28M$-53.47M$-61.04B----
Avg Forecast$-93.72M$-54.88M$-50.98M$-52.00M$-46.52M$-47.15M$-46.66M$-24.44M
High Forecast$-93.72M$-54.88M$-48.88M$-46.16M$-26.92M$-23.50M$-21.06M$-24.44M
Low Forecast$-93.72M$-54.88M$-53.09M$-57.84M$-66.12M$-70.79M$-72.26M$-24.44M
Surprise %-64.22%-10.21%4.88%117286.69%----

IMRX Forecast FAQ

Is Immuneering stock a buy?

Immuneering stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immuneering is a favorable investment for most analysts.

What is Immuneering's price target?

Immuneering's price target, set by 11 Wall Street analysts, averages $30 over the next 12 months. The price target range spans from $30 at the low end to $30 at the high end, suggesting a potential 376.19% change from the previous closing price of $6.3.

How does Immuneering stock forecast compare to its benchmarks?

Immuneering's stock forecast shows a 376.19% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Immuneering over the past three months?

  • October 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Immuneering’s EPS forecast?

Immuneering's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.57, marking a -99.92% decrease from the reported $-2.036K in 2024. Estimates for the following years are $-1.74 in 2026, $-1.5 in 2027, and $-0.86 in 2028.

What is Immuneering’s revenue forecast?

Immuneering's average annual revenue forecast for its fiscal year ending in December 2025 is $1.09M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $21.27M, followed by $33.4M for 2027, and $70.43M for 2028.

What is Immuneering’s net income forecast?

Immuneering's net income forecast for the fiscal year ending in December 2025 stands at $-46.52M, representing a -99.92% decrease from the reported $-61.037B in 2024. Projections indicate $-47.148M in 2026, $-46.661M in 2027, and $-24.438M in 2028.